Reduced Default Mode Connectivity in Adolescents With Conduct Disorder - 24/08/16

Abstract |
Objective |
Conduct disorder (CD) is characterized by impulsive, aggressive, and antisocial behaviors that might be related to deficits in empathy and moral reasoning. The brain’s default mode network (DMN) has been implicated in self-referential cognitive processes of this kind.
Method |
This study examined connectivity between key nodes of the DMN in 29 adolescent boys with CD and 29 age- and sex-matched typically developing adolescent boys. The authors ensured that group differences in DMN connectivity were not explained by comorbidity with other disorders by systematically controlling for the effects of substance use disorders (SUDs), attention-deficit/hyperactivity disorder (ADHD) symptoms, psychopathic traits, and other common mental health problems.
Results |
Only after adjusting for co-occurring ADHD symptoms, the group with CD showed hypoconnectivity between core DMN regions compared with typically developing controls. ADHD symptoms were associated with DMN hyperconnectivity. There was no effect of psychopathic traits on DMN connectivity in the group with CD, and the key results were unchanged when controlling for SUDs and other common mental health problems.
Conclusion |
Future research should directly investigate the possibility that the aberrant DMN connectivity observed in the present study contributes to CD-related deficits in empathy and moral reasoning and examine self-referential cognitive processes in CD more generally.
Le texte complet de cet article est disponible en PDF.Key words : conduct disorder, ADHD, psychopathic traits, default mode network, functional connectivity
Plan
| This work was funded in part by awards to Edmund Sonuga-Barke and Graeme Fairchild from the University of Southampton that funded PhD studentships for M. John Broulidakis and Kate Sully, respectively. |
|
| The authors thank the participants and their families for taking part in the study and the radiographers involved in MRI scanning. |
|
| Disclosure: Dr. Fairchild has received grants from the Medical Research Council (MRC), the European Commission, the National Council for Science and Technology, Mexico, and the charity Kids Company. Dr. Blumensath has received grant or research support from the Engineering and Physical Sciences Research Council and Innovate UK, the innovations agency in the United Kingdom. He is a named inventor on patent application WO2014162300 A1. Dr. Sonuga-Barke has received grant support from the MRC, the Economic and Social Research Council, the Wellcome Trust, the Solent National Health Service Trust, the European Commission, the Child Health Research Foundation New Zealand, the National Institute for Health Research, the Nuffield Foundation, Fonds Wetenschappelijk OnderzoekVlaanderen, and MQ: Transforming Mental Health. He has received speaker fees, research funding, and conference support from and has served as a consultant to Shire Pharma. He has received speaker fees from Janssen-Cilag. He has served as a consultant to Neurotech Solutions, Aarhus University, Copenhagen University, and Berhanderling, Skolerne, Copenhagen, KU Leuven. He has received book royalties from Oxford University Press and Jessica Kingsley. Drs. Sully and Darekar and Mr. Broulidakis report no biomedical financial interests or potential conflicts of interest. |
Vol 55 - N° 9
P. 800 - septembre 2016 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
